359600-10-5
359600-10-5
Chemical Structure
RNPA1000
- CAS No.: 359600-10-5
- Formula:C23H18BrN3O3
- Molecular Weight:464.31
IUPAC Name: (E)-4-(3-(3-((3-bromophenyl)amino)-2-cyano-3-oxoprop-1-en-1-yl)-2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid
InChIKey: WQCMDUBFZYCGMI-WOJGMQOQSA-N
SMILES: O=C(O)C1=CC=C(N2C(C)=C(/C=C(C#N)/C(NC3=CC=CC(Br)=C3)=O)C=C2C)C=C1
Biological Activity: RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RNPA1000 | 98.15% | RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RNPA1000 (Standard) | ≥98% | RNPA1000 (Standard) is the analytical standard of RNPA1000 (HY-12824). This product is intended for research and analytical applications. RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Eidem TM, et al. Drug-eluting cements for hard tissue repair: a comparative study using vancomycin and RNPA1000 to inhibit growth of Staphylococcus aureus. J Biomater Appl. 2014 Apr;28(8):1235-46. [Content Brief]
- [2]. Eidem TM, et al. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28. [Content Brief]
- [3]. Patrick D Olson, et al. Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis. PLoS Pathog. 2011 Feb 10;7(2):e1001287. [Content Brief]
